In a rare instance of bipartisan agreement, lawmakers agree that drug prices are too high. President Trump has pledged to address this problem.
Express Scripts has been targeted in the past as "low-hanging fruit" in the effort to contain soaring prices. The company's defense that ESRX is a cost manager may be disregarded.
Additionally, the $67 billion Cigna deal for Express Scripts has been in question from a regulatory approval standpoint. Trump's new policy outlines could increase the uncertainty for this potential deal.